BHCM
IOVA icon

Brevan Howard Capital Management’s Iovance Biotherapeutics IOVA Stock Holding History

Brevan Howard Capital Management’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$282K Buy
+80,353
New +$257K ﹤0.01% 1662

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

Brevan Howard Capital Management's IOVA Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 525,519 shares — an estimated $1.68M sold.

Brevan Howard Capital Management first reported a position in IOVA in Q2 2022 and held it in 15 quarters. The position peaked at $10.4M in Q2 2023. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 525,519 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.68M.
  • Brevan Howard Capital Management first reported a position in Iovance Biotherapeutics in Q2 2022 and held it in 15 quarters.
  • Brevan Howard Capital Management's Iovance Biotherapeutics position peaked at $10.4M in Q2 2023.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.